A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson B, Hains AB, Chen C, Galanter J, Burgess BL, Cho W, et al. Ann Clin Transl Neurol. 2022 Jan; 9(1):50-66. Epub 2022 Jan 10.